Osmosis Investment Management UK Ltd Acquires New Holdings in Natera, Inc. $NTRA

Key Points

• Osmosis Investment Management acquired 3,275 Natera shares worth approximately $889,000 in the second quarter. Institutional investors and hedge funds now own 99.90% of the company.
• Natera insiders sold 177,955 shares valued at roughly $40.7 million over the past three months, including significant sales by the CEO and a director under pre-arranged trading plans.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $319.38. Natera’s latest quarterly revenue rose 37.7% year over year to $752.75 million, while its adjusted loss per share beat estimates.

Osmosis Investment Management UK Ltd bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,275 shares of the medical research company's stock, valued at approximately $889,000.

Several other hedge funds also recently bought and sold shares of NTRA. BlackRock Inc. bought a new stake in shares of Natera in the 2nd quarter valued at $2,962,770,000. Coatue Management LLC grew its stake in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the period. Wellington Management Group LLP increased its holdings in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank acquired a new stake in shares of Natera during the fourth quarter worth about $372,398,000. Finally, JPMorgan Chase & Co. raised its position in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director owned 4,250 shares of the company's stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the company's stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. The trade was a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 177,955 shares of company stock worth $40,704,193 over the last three months. Company insiders own 5.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Wall Street Zen lowered Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a report on Friday, July 17th. Barclays reaffirmed an "overweight" rating and issued a $340.00 price target on shares of Natera in a research note on Friday, August 7th. Zacks Research raised shares of Natera from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Finally, Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They set an "outperform" rating and a $310.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $319.38.

Natera Trading Down 1.3%

Shares of NTRA opened at $327.72 on Tuesday. Natera, Inc. has a 12 month low of $157.43 and a 12 month high of $333.56. The firm has a fifty day simple moving average of $276.45 and a 200 day simple moving average of $230.09. The stock has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period in the previous year, the business earned ($0.74) EPS. The company's revenue was up 37.7% compared to the same quarter last year. As a group, research analysts predict that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source